INVERSAGO-PHARMA
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as its pipeline of other peripherally-acting CB1 inverse agonists in several other indications.
“The appointment of a Chief Medical Officer is an essential element of our corporate strategy as we have entered the clinical phase with our lead compound”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Glenn brings a broad range of relevant experiences in all aspects of drug development and regulatory interactions and I trust he will have a strong impact on the science we develop at Inversago, helping us meet our objective: developing safe and potent inverse agonists of peripheral CB1 receptors”, added Dr. Ravenelle.
“I am very excited to join Inversago and work to bring new therapies to market for patients suffering from Prader-Willi syndrome and other metabolic disorders, using a mechanism that has proven its high therapeutic potential”, said Glenn D. Crater, MD, FCCP, Chief Medical Officer of Inversago Pharma.
Dr. Crater brings more than 20 years of experience in clinical development and medical affairs, including in rare diseases. Prior to joining Inversago, Glenn held many executive positions, including Vice President, Clinical Development and Medical Affairs at Theravance Biopharma and Aerocrine, as well as Country Medical Director for GSK Canada. Glenn holds a MD degree from the University of Tennessee and is Board Certified in Internal Medicine, Pulmonary Diseases.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of Dr. Crater available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005301/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas
Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 11:00:00 CET | Press release
Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales
Hanshow and Unide Partner to Advance Store Modernization under the “Plan Unide 2.0” Strategy31.10.2025 02:45:00 CET | Press release
Hanshow, a global leader in digital retail solutions, has announced a strategic collaboration with Unide Corporativa, one of Spain’s most established food retail cooperatives, to advance store digitalization and operational efficiency under its new strategic roadmap “Plan Unide 2.0” (2025–2028). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030921658/en/ Founded over 90 years ago, Unide unites hundreds of independent grocery retailers across Spain under a cooperative model built on proximity, freshness, and community service. With Plan Unide 2.0, the cooperative aims to strengthen competitiveness through member business development, store modernization, and new store openings—a roadmap to ensure sustainable growth in an evolving retail landscape. Unide faces operational challenges common to cooperative retail: manual paper label updates, inconsistent pricing, and limited promotional agility across its network. Meanwhile,
IFF Declares Dividend for Fourth Quarter 202530.10.2025 21:15:00 CET | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 9, 2026 to shareholders of record as of December 19, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20251030551985/en/
Rimini Street Announces Fiscal Third Quarter 2025 Financial and Operating Results30.10.2025 21:01:00 CET | Press release
Third Quarter Financial Highlights Include: Remaining Performance Obligations (RPO) of $611.2 million, up 6.4% from the prior year Adjusted Calculated Billings of $63.9 million, up 6.7% from the prior year Active Clients of 3,155, up 1.9% from the prior year Rimini Street, Inc. (the “Company”) (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal third quarter ended September 30, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030625900/en/ Rimini Street Announces Fiscal Third Quarter 2025 Financial and Operating Results Select Third Quarter 2025 Financial Results Revenue was $103.4 million for the third quarter of 2025, a decrease of 1.2% compared to $104.7 million for the same period last year; excluding the wind dow
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom